BSX

Business Context and Reporting Period

Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2000
Business Overview: A worldwide developer, manufacturer, and marketer of medical devices for less invasive procedures. Operations are reported across four geographic segments: United States, Europe, Japan, and Inter-Continental.

Key Financial Metrics

Note: Total Debt calculated as Commercial Paper ($249M) + Bank Obligations ($194M) + Long-term Debt ($567M) for Q2 2000.

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 4% year-over-year for both the quarter and the six-month period. This was driven primarily by a 9% decline in U.S. revenues and a 6% drop in worldwide vascular sales, specifically due to reduced sales of the NIR(R) coronary stent in the U.S. ($78M in Q2 2000 vs. $106M in Q2 1999).
• Profitability Increase: Despite lower sales, Net Income increased 12% for the quarter and 9% year-to-date. This was achieved through improved gross margins (benefiting from inventory management and favorable foreign exchange), reduced interest expense (due to debt paydown), and a lower effective tax rate (30% vs. 34% prior year).
• Expense Management: Selling, general, and administrative (SG&A) expenses increased as a percentage of sales (31% vs. 28% in Q2 1999) due to sales declines and increased costs to expand the sales force. Interest expense dropped significantly ($19M in Q2 2000 vs. $35M in Q2 1999).
• Balance Sheet: Working capital improved to $27 million (from break-even at year-end 1999). The company reduced total debt by approximately $265 million during the first half of 2000.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Sales Forecast: Management expects net sales for the second half of 2000 to be relatively flat compared to 1999.
• Global Operations Plan: Announced in July 2000, this plan includes a "plant optimization initiative" expected to incur pre-tax charges of approximately $70 million ($45 million after-tax) in 2000. The initiative aims to consolidate manufacturing and R&D facilities.
• Future Savings: The plan is estimated to generate pre-tax operating savings of $110 million in 2001, $220 million in 2002, and $250 million annually thereafter.
• Capital Needs: The company expects to incur $55 million in capital expenditures and $50 million in tax payments for the remainder of 2000, funded by operating cash flows and borrowing capacity.

Risks and Contingencies

• Supply Chain Risk: The company relies on Medinol Ltd. for NIR(R) coronary stents. At June 30, 2000, inventory was $129 million with a commitment to purchase an additional $53 million. Supply interruptions could materially impact results.
• Legal Proceedings: The company is involved in extensive patent litigation with competitors including Guidant, Johnson & Johnson (Cordis), Medtronic, and Cook Inc. Potential exposure for litigation-related costs is estimated between $35 million and $50 million, with a current accrual of $35 million.
• Regulatory Investigations: The U.S. Department of Justice is investigating the voluntary recall of the NIR ON(R) Ranger(TM) with Sox(TM) coronary stent. The FTC is also investigating compliance with a 1995 Consent Order regarding intravascular ultrasound technology.
• Market Volatility: The coronary stent market is highly competitive with significant volatility. Future revenues depend on regulatory approvals for new stent platforms.

Investor Verification Checklist

• Stent Inventory Levels: Verify the status of the $129 million NIR(R) stent inventory and the $53 million purchase commitment to assess potential write-down risks.
• Restructuring Charges: Monitor the timing and magnitude of the $70 million pre-tax charges associated with the new global operations plan.
• Legal Reserves: Track the outcome of major patent lawsuits (specifically against Guidant, Cordis, and Medtronic) to determine if the $35 million accrual is sufficient.
• Debt Maturity: Confirm the renewal of the $600 million 364-day credit facility expiring in September 2000.
• Regulatory Approvals: Watch for FDA or international regulatory approvals for new coronary and peripheral stent platforms, which are critical for future revenue growth.